Evidence map›Paper›PMID 30410075›Full record

ArticleScientific reports2018

Amino acid modified [70] fullerene derivatives with high radical scavenging activity as promising bodyguards for chemotherapy protection.

Yue Zhou, Mingming Zhen, Mirong Guan, Tong Yu, Liang Ma, Wei Li, Jiasheng Zheng, Chunying Shu, Chunru Wang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Thiophene-based water-soluble CBiomaterials translational · 2025
    Article
  3. Review
  4. Review
  5. CNanoscale · 2022
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yue ZhouCAS Key Laboratory of Molecular Nanostructure and Nanotechnology, and Beijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, 100190, Beijing, China.
Mingming ZhenCAS Key Laboratory of Molecular Nanostructure and Nanotechnology, and Beijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, 100190, Beijing, China. zhenmm@iccas.ac.cn.
Mirong GuanCAS Key Laboratory of Molecular Nanostructure and Nanotechnology, and Beijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, 100190, Beijing, China.
Tong YuCAS Key Laboratory of Molecular Nanostructure and Nanotechnology, and Beijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, 100190, Beijing, China.
Liang MaCenter of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, 100069, Beijing, China.
Wei LiCenter of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, 100069, Beijing, China.
Jiasheng ZhengCenter of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, 100069, Beijing, China.
Chunying ShuCAS Key Laboratory of Molecular Nanostructure and Nanotechnology, and Beijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, 100190, Beijing, China.
Chunru WangCAS Key Laboratory of Molecular Nanostructure and Nanotechnology, and Beijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, 100190, Beijing, China. crwang@iccas.ac.cn.ORCID http://orcid.org/0000-0001-7984-6639
Chinese Academy of Sciences · CNCapital Medical University · CNBeijing National Laboratory for Molecular Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the great efforts for tumor therapy in the last decades, currently chemotherapy induced toxicity remains a formidable problem for cancer patients, and it usually prohibits the cancer therapy from successful completion due to severe side effects. In general, the main side effects of chemotherapeutic agents are from the as-produced reactive oxygen species (ROS) that not only harm the tumor cells but also damage the patients' organs. Here we report the application of amino acid derivatives of fullerene (AADF) in the chemotherapy which strongly scavenge the excess ROS to protect the tested mice against the chemotherapy-induced hepatotoxicity and cardiotoxicity. Two amino acids, i.e., L-lysine and β-alanine were separately employed to chemically modify C

Indexed as

Amino AcidsAnimalsAntineoplastic Agentsbeta-AlanineCardiotoxicityChemical and Drug Induced Liver InjuryCytochrome P-450 CYP2E1DoxorubicinFemaleFree Radical ScavengersFullerenesGlutathioneHumansHuman Umbilical Vein Endothelial CellsLysineMiceAmino AcidsAntineoplastic Agentsbeta-Alaninecytochrome P-450 2E1, mouseCytochrome P-450 CYP2E1DoxorubicinFree Radical ScavengersFullerenesGlutathioneLysineReactive Oxygen Species

Identifiers

PMID30410075
PMCPMC6224443
OpenAlexW2899268427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.